Drug Price Trends for NDC 60505-3140

Average Pharmacy Cost for 60505-3140

Drug Name	NDC	Price/Unit ($)	Unit	Date
OLANZAPINE 20 MG TABLET	60505-3140-00	0.15058	EACH	2026-03-18
OLANZAPINE 20 MG TABLET	60505-3140-03	0.15058	EACH	2026-03-18
OLANZAPINE 20 MG TABLET	60505-3140-08	0.15058	EACH	2026-03-18
OLANZAPINE 20 MG TABLET	60505-3140-00	0.14838	EACH	2026-02-18
OLANZAPINE 20 MG TABLET	60505-3140-08	0.14838	EACH	2026-02-18
OLANZAPINE 20 MG TABLET	60505-3140-03	0.14838	EACH	2026-02-18
OLANZAPINE 20 MG TABLET	60505-3140-08	0.14983	EACH	2026-01-21

Best Wholesale Price for NDC 60505-3140

These are wholesale prices available to the US Federal Government which, by law, must be the best prices available under comparable terms and conditions

Price type key: Federal Supply Schedule (FSS): generally available to all Federal Govt agencies / 'BIG4' prices: VA, DoD, Public Health & Coast Guard only / National Contracts (NC): Available to specific agencies

Drug Name	Vendor	NDC	Count	Price ($)	Price/Unit ($)	Dates	Price Type
OLANZAPINE 20MG TAB	Golden State Medical Supply, Inc.	60505-3140-03	30	11.27	0.37567	2023-06-15 - 2028-06-14	FSS
OLANZAPINE 20MG TAB	Golden State Medical Supply, Inc.	60505-3140-08	1000	340.29	0.34029	2023-06-15 - 2028-06-14	FSS

Market Analysis and Price Projections for ND98: 60505-3140

Last updated: February 25, 2026

What is the drug identified as NDC 60505-3140?

NDC 60505-3140 is a prescription drug marketed as [Drug Name]. It is approved for [indications]. The drug is available in [formulation, e.g., tablet, injection], with strengths of [strengths].

What is the current market landscape?

Market size and sales volume

• Estimated global sales in 2022: $[value] billion.
• U.S. market share: [percentage]% of total sales.
• Annual sales growth rate (2018-2022): [percentage]%.

Key competitors and market positions

Drug Name	Market Share	Indications	Formulation	Price (per unit)	Notes
[Competitor 1]	[x]%	[indications]	[formulation]	$[value]	First-line treatment in US market
[Competitor 2]	[x]%	[indications]	[formulation]	$[value]	Recently launched alternative

Regulatory and reimbursement status

• FDA approval date: [date].
• CMS reimbursement policies: Covered under [Medicare/Medicaid/Private] plans.
• Open formulary or restricted access: [status].

How is the current pricing structured?

List prices and discounts

• Official list price: $[list price] per unit.
• Average net price after discounts: $[net price].
• Average wholesale acquisition cost (WAC): $[WAC].

Factors affecting pricing

• Patent exclusivity extending until [year].
• Market entry of biosimilars or generics: Not present or projected for [years].
• Manufacturer's rebate and discount strategies: Estimated [percentage]% reduction.

Future market trends and projections

Sales growth forecasts

Year	Projected Sales	Compound Annual Growth Rate (CAGR)
2023	$[value]	[x]%
2024	$[value]	[x]%
2025	$[value]	[x]%

• The market is expected to grow at a CAGR of [percentage]% over the next three years, driven by increased approval for additional indications and expanded access.

Price trend projections

• List prices are forecasted to remain stable through 2024, followed by potential increases of [percentage]% annually due to inflation, R&D costs, or market dynamics.

Key market drivers

• Expanded indications increasing patient eligibility.
• Patent protection decreasing competition in the short term.
• Pricing pressure from biosimilar and generic market entrants expected post-[year].

What are the risks and uncertainties?

• patent expirations projected for [year].
• Regulatory changes impacting drug reimbursement.
• Competitive entry of biosimilars reducing market share and price.
• Potential safety concerns or adverse events.

Price projections summary

Year	Estimated list price	Expected net price	Anticipated sales volume	Revenue projection
2023	$[value]	$[value]	[quantity]	$[value]
2024	$[value]	$[value]	[quantity]	$[value]
2025	$[value]	$[value]	[quantity]	$[value]

Key Takeaways

• The drug is positioned in a market valued at $[value] with growth forecasts driven by indication expansion.
• Current pricing is stable but expected to increase modestly, influenced by patent protections and market dynamics.
• Key competitors hold significant market shares, but patent cliffs and biosimilar entries pose future risks.
• Revenue depends on regulatory status, reimbursement policies, and competitive pressures over the next three years.

FAQs

1. When will patent expiry likely impact the drug’s market share?

   • Patent expiration is projected for [year], which could open the market to biosimilars or generics.

2. What are the main factors influencing price increases?

   • Inflation, R&D costs, regulatory fees, and limited competition during patent exclusivity.

3. How does reimbursement policy affect the drug’s price?

   • Reimbursement at the Medicare or private payer level influences net price, with rebate strategies adjusting effective revenues.

4. Are biosimilars or generics expected to enter soon?

   • No immediate biosimilar entry is projected until after [year], but the landscape could change with patent challenges.

5. What market segments are expected to see the highest growth?

   • Indications with expanding approved uses and underserved patient populations are likely to drive the most growth.

---

References

[1] U.S. Food and Drug Administration. (2022). Drug Approvals and Safety Communications.

[2] IQVIA. (2022). The Global Use of Medicine in 2022.

[3] Centers for Medicare & Medicaid Services. (2022). National Fee Schedule and Reimbursement Policies.

[4] EvaluatePharma. (2022). World Pharmaceutical Market Analysis.